NASDAQ : KALA

KALA BIO, Inc.

$0.755 USD

$0.01 (0.96%)

Volume
124.22K
Average Volume
117.39K
Market Capitalization
$14.6M
P/E Ratio
-0.26
Dividend Yield
0.00%
Price Target
$18.25
Year High
$1030.00
Year Low
$0.59
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.91
Company Overview

NASDAQ

Avi Minkowitz

Biotechnology

Healthcare

KALA

6

US

USD

https://www.kalarx.com

781 996 5252

483119301

0001479419

Liquidity Metrics

0.00

7.91

7.91

1.13

0.00

Sales & Valuation

-$

0.00

0.57

-0.56

-3.20

Profitability

-$3.31

-$26.98M

0.00%

0.00%

-1335.64%

-159.56%

P/E Metrics

-0.26

0.00

0.00

Analyst Price Target & Rating

$18.25

$35.00

$1.50

Strong Sell

1/5

11 Analysts

-95.86%

Financial Health Scores

-77.22

2/9

$10.76M

$12.32M

$1.56M

-$17.47M

Key Metrics (TTM)

$12.7M

0.00

-0.74

7.91

-1335.64%

-281.52%

-322.55%

-180.21%

-7057 days

Company Executives
Name Title
Mary Reumuth Treasurer & Secretary
Vincent Kosewski Senior Vice President of Manufacturing & Supply Chain Management
Jill S. Steier Executive Director of Investor Relations & Corporation Communications
Francis S. Mah Chief Medical Advisor
Justin Hanes Founder & Chair of the Scientific Advisory Board
Avi Minkowitz CEO, CFO & Director
Carl Rennie Executive Director of Account Management
Patrick Bedell Executive Director of Trade & Alternate Channels
Josiah Craver Senior Vice President & Corporate Controller
Poll Results

No votes yet today — be the first to share your view!

About KALA BIO, Inc. (NASDAQ:KALA) Stock

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts. ...

KALA BIO (KALA) Expected to Post Earnings on Thursday

2026-07-30 03:31:35

KALA BIO (NASDAQ: KALA - Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect KALA BIO to post earnings of ($6.00) per share for the quarter. Parties can find conference call details on the company's upcoming Q2 2026 earning report for the latest details

Frequently Asked Questions

What is the current KALA BIO, Inc. (KALA) stock price?

KALA BIO, Inc.(NASDAQ:KALA) stock price is $0.755 in the last trading session. During the trading session, KALA stock reached the peak price of $1030 while $0.59 was the lowest point it dropped to. The percentage change in KALA stock occurred in the recent session was 0.96% while the dollar amount for the price change in KALA stock was $0.01.

KALA's industry and sector of operation?

The NASDAQ listed KALA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of KALA?

Mary Reumuth | Treasurer & Secretary
Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management
Jill S. Steier | Executive Director of Investor Relations & Corporation Communications
Francis S. Mah | Chief Medical Advisor
Justin Hanes | Founder & Chair of the Scientific Advisory Board

How many employees does KALA have?

Number of KALA employees currently stands at 6. KALA operates from 1167 Massachusetts Avenue, Arlington, MA 02476, US.

Link for KALA official website?

Official Website of KALA is: https://www.kalarx.com

How do I contact KALA?

KALA could be contacted at phone #781 996 5252 and can also be accessed through its website. KALA operates from 1167 Massachusetts Avenue, Arlington, MA 02476, US.

How many shares of KALA are traded daily?

The average number of KALA shares traded daily for last 3 months was 117.39K.

What is the market cap of KALA currently?

The market value of KALA currently stands at $14.6M with its latest stock price at $0.755